SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

CORAL GABLES, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the third quarte…

RLMD

Related stories